The Technical Analyst
Entrada Therapeutics, [TRDA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Entrada Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
2.02% $12.15
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 408.25 mill |
| EPS: | -0.200 |
| P/E: | -60.75 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 33.60 mill |
| Avg Daily Volume: | 0.0760 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -60.75 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -10.33x |
| Company: PE -60.75 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 11.27 - 13.03 ( +/- 7.28%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-08 | Kim Peter S | Buy | 2 600 | Common Stock |
| 2024-03-28 | Kim Peter S | Buy | 1 512 | Common Stock |
| 2024-03-26 | Kim Peter S | Buy | 2 750 | Common Stock |
| 2024-03-25 | Kim Peter S | Buy | 3 180 | Common Stock |
| 2024-03-22 | Kim Peter S | Buy | 3 118 | Common Stock |
| INSIDER POWER |
|---|
| 70.07 |
| Last 99 transactions |
| Buy: 995 092 | Sell: 209 386 |
Forecast:
16:00 - $12.11
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $12.11
Forecast 2: 16:00 - $12.11
Forecast 3: 16:00 - $12.11
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $12.15 (2.02% ) |
| Volume | 0.0855 mill |
| Avg. Vol. | 0.0760 mill |
| % of Avg. Vol | 112.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TRDA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:18 | sell | $14.52 | N/A | Active |
|---|
TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2024-03-13 07:00:00 - Press Release
Entrada Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results
– cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of december 31, 2023 – – completed dosing for third cohort of phase 1 clinical trial of entr-601-44 for the potential treatment of dmd with data readout on track for the second half of 2024 – – regulatory applications expected in the fourth quarter of 2024 for the global phase 2 clinical development of entr-601-44 and entr-601-45 in people living with dmd – boston, march 13, 2024 (globe newswire) -- entrada therapeutics, inc. (nasdaq: trda) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible...
2024-02-07 07:00:00 - Press Release
Entrada Therapeutics To Present At Upcoming Investor Conferences
Boston, feb. 07, 2024 (globe newswire) -- entrada therapeutics, inc. (nasdaq: trda), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular endosomal escape vehicle (eev™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences:
2023-12-18 19:40:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - Trda
New york , dec. 18, 2023 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of entrada therapeutics, inc. ("entrada" or the "company") (nasdaq: trda). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2023-11-29 13:39:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - Trda
New york , nov. 29, 2023 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of entrada therapeutics, inc. ("entrada" or the "company") (nasdaq: trda). such investors are advised to contact robert s.
2023-11-22 07:00:00 - Press Release
Entrada Therapeutics Announces Updates On Entr-601-44 In Duchenne Muscular Dystrophy
– company completes dosing of first and second cohorts in phase 1 clinical trial, entr-601-44-101 – – entr-601-44 clinical development program remains on track with data readout expected in second half of 2024 – – u.s. fda clinical hold on ind application remains in effect – – cash runway expected through 2025 – boston, nov. 22, 2023 (globe newswire) -- entrada therapeutics, inc. (nasdaq: trda), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular endosomal escape vehicle (eev™)-therapeutics as a new class of medicines, today announced the completion of dosing for the first and second cohorts of its phase 1 clinical trial, entr-601-44-101...
Latest News
2024-03-18 10:15:34 - Zacks Investment Research
New Strong Sell Stocks for March 18th
ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.
2023-11-23 13:31:31 - Zacks Investment Research
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug
Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.
2023-11-22 11:52:53 - Proactive Investors
Entrada Therapeutics shares tumble as FDA refuses to lift hold on muscular dystrophy trial
Entrada Therapeutics shares plummeted almost 30% after it announced that the U.S. Food and Drug Administration (FDA) has refused to lift its clinical hold on its Phase 1 study of its investigational therapeutic ENTR-601-44 for Duchenne muscular dystrophy.
2023-11-07 09:46:42 - Zacks Investment Research
Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of a loss of $0.55 per share. This compares to loss of $0.80 per share a year ago.
2023-10-12 07:00:00 - GlobeNewsWire
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences:
2023-08-29 07:00:00 - GlobeNewsWire
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the Company will participate in two investor conferences in September.
2023-07-21 08:27:21 - Zacks Investment Research
New Strong Buy Stocks for July 21st
TRDA, LPRO, TBBK, BMTX and MOTS have been added to the Zacks Rank #1 (Strong Buy) List on July 21, 2023.
2022-12-09 15:03:15 - Zacks Investment Research
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.
2022-12-08 08:24:33 - Market Watch
Entrada Therapeutics shares jump on collaboration with Vertex
Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. VRTX, +1.85% that aims to develop treatments for myotonic dystrophy type 1, a genetic disorder that causes progressive muscle weakness. The collaboration includes Entrada's ENTR-701, which is currently in preclinical studies.
2022-08-30 07:00:00 - GlobeNewsWire
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Nathan Dowden, Chief Operating Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 – 14, 2022.